LEXINGTON, Mass., June 20, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of various cancers, today announced the issuance of U.S. Patent No. 8,461,157, which claims methods of treating human diseases or disorders mediated by one or more of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR) and histone deacetylase (HDAC) proteins, using compounds from a genus of small molecules with dual inhibitory properties, including but not limited to CUDC-907, a proprietary clinical stage dual inhibitor of PI3K and HDAC enzymes. This patent, along with another related patent issued in February 2013 (U.S. Patent No. 8,367,663), significantly enhances the intellectual property portfolio for Curis' proprietary chemical entities that target PI3K and HDAC, and in some instances mTOR, within a single molecule for the treatment of certain human diseases.
Curis Announces U.S. Patent Issuance Strengthening Intellectual Property Position Of PI3K-HDAC Inhibitor CUDC-907
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts